Aeon Biopharma Inc
AEON1.070USD
+0.060+5.94%
收盘 12/19, 16:00（美东）报价延迟15分钟
12.46M总市值
0.37市盈率 TTM
关于 Aeon Biopharma Inc 公司
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.
Aeon Biopharma Inc简介
公司代码AEON
公司名称Aeon Biopharma Inc
上市日期Feb 09, 2021
CEOBancroft (Robert E)
员工数量5
证券类型Ordinary Share
年结日Feb 09
公司地址5 Park Plaza
城市IRVINE
上市交易所NASDAQ OMX – NASDAQ Basic Amex
国家United States of America
邮编92614
电话19493546499
网址https://aeonbiopharma.com/
公司代码AEON
上市日期Feb 09, 2021
CEOBancroft (Robert E)
Aeon Biopharma Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Jost Fischer
Mr. Jost Fischer
Independent Chairman of the Board
Independent Chairman of the Board
170.61K
+27868.85%
Mr. Robert J. (Bob) Palmisano
Mr. Robert J. (Bob) Palmisano
Independent Director
Independent Director
31.46K
--
Mr. Marc Forth
Mr. Marc Forth
Director
Director
973.00
--
Mr. Robert Bancroft
Mr. Robert Bancroft
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Shelley Thune
Ms. Shelley Thune
Independent Director
Independent Director
--
--
Mr. Alex Wilson
Mr. Alex Wilson
Executive Vice President, Chief Legal Officer, Corporate Secretary
Executive Vice President, Chief Legal Officer, Corporate Secretary
--
--
Ms. Jennifer Sy
Ms. Jennifer Sy
Principal Financial Officer, Chief Accounting Officer
Principal Financial Officer, Chief Accounting Officer
--
-100.00%
Mr. Seongsoo Park
Mr. Seongsoo Park
Director
Director
--
--
Dr. Eric Carter, M.D., Ph.D.
Dr. Eric Carter, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Chad Oh, M.D.
Dr. Chad Oh, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Jost Fischer
Mr. Jost Fischer
Independent Chairman of the Board
Independent Chairman of the Board
170.61K
+27868.85%
Mr. Robert J. (Bob) Palmisano
Mr. Robert J. (Bob) Palmisano
Independent Director
Independent Director
31.46K
--
Mr. Marc Forth
Mr. Marc Forth
Director
Director
973.00
--
Mr. Robert Bancroft
Mr. Robert Bancroft
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Shelley Thune
Ms. Shelley Thune
Independent Director
Independent Director
--
--
Mr. Alex Wilson
Mr. Alex Wilson
Executive Vice President, Chief Legal Officer, Corporate Secretary
Executive Vice President, Chief Legal Officer, Corporate Secretary
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 12月4日 周四
更新时间: 12月4日 周四
持股股东
股东类型
持股股东
持股股东
占比
Chernett (Jorey)
9.53%
Dauntless Investment Group, LLC
9.50%
L1 Global Manager Pty Limited
3.93%
Alta Partners L.L.C
2.11%
Bancroft (Robert E.)
1.50%
其他
73.43%
持股股东
持股股东
占比
Chernett (Jorey)
9.53%
Dauntless Investment Group, LLC
9.50%
L1 Global Manager Pty Limited
3.93%
Alta Partners L.L.C
2.11%
Bancroft (Robert E.)
1.50%
其他
73.43%
股东类型
持股股东
占比
Investment Advisor
14.66%
Individual Investor
12.75%
Corporation
2.11%
Hedge Fund
0.57%
Investment Advisor/Hedge Fund
0.40%
Research Firm
0.26%
Venture Capital
0.14%
其他
69.11%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
67
1.90M
16.13%
--
2025Q3
68
1.90M
16.40%
+93.23K
2025Q2
77
1.87M
15.05%
-257.13K
2025Q1
85
2.12M
3.61%
+1.74M
2024Q4
142
173.55K
77.76%
-9.58K
2024Q3
144
183.13K
72.76%
+52.30K
2024Q2
141
131.03K
75.18%
-1.02K
2024Q1
144
132.04K
79.55%
-289.14K
2023Q4
143
120.98K
87.85%
+3.34K
2023Q3
138
117.65K
75.77%
+54.36K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Chernett (Jorey)
1.13M
9.69%
+1.13M
--
May 27, 2025
Dauntless Investment Group, LLC
1.13M
9.66%
+100.00K
+9.76%
Jun 30, 2025
Alta Partners L.L.C
586.34K
5.04%
-43.28K
-6.87%
Jun 30, 2025
Bancroft (Robert E.)
177.10K
1.52%
+177.10K
--
May 14, 2025
Fischer (Jost)
170.61K
1.47%
+170.00K
+27868.85%
May 21, 2025
Geode Capital Management, L.L.C.
20.70K
0.18%
+20.70K
--
Jun 30, 2025
Blue Owl Capital Holdings LP
42.35K
0.36%
--
--
Jun 30, 2025
Bigger Capital Funds, LP
34.03K
0.29%
+34.03K
--
Jan 06, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jan 23, 2025
Merger
0→0
Jan 23, 2025
Merger
72→1
Jan 23, 2025
Merger
72→1
Jan 23, 2025
Merger
72→1
公告日期
类型
比率
Jan 23, 2025
Merger
0→0
Jan 23, 2025
Merger
72→1
Jan 23, 2025
Merger
72→1
Jan 23, 2025
Merger
72→1
常见问题
Aeon Biopharma Inc的前五大股东是谁？
Aeon Biopharma Inc 的前五大股东如下：
Chernett (Jorey)持有股份：1.13M，占总股份比例：9.69%。
Dauntless Investment Group, LLC持有股份：1.13M，占总股份比例：9.66%。
Alta Partners L.L.C持有股份：586.34K，占总股份比例：5.04%。
Bancroft (Robert E.)持有股份：177.10K，占总股份比例：1.52%。
Fischer (Jost)持有股份：170.61K，占总股份比例：1.47%。
Chernett (Jorey)持有股份：1.13M，占总股份比例：9.69%。
Dauntless Investment Group, LLC持有股份：1.13M，占总股份比例：9.66%。
Alta Partners L.L.C持有股份：586.34K，占总股份比例：5.04%。
Bancroft (Robert E.)持有股份：177.10K，占总股份比例：1.52%。
Fischer (Jost)持有股份：170.61K，占总股份比例：1.47%。
Aeon Biopharma Inc的前三大股东类型是什么？
Aeon Biopharma Inc 的前三大股东类型分别是：
Chernett (Jorey)
Dauntless Investment Group, LLC
L1 Global Manager Pty Limited
Chernett (Jorey)
Dauntless Investment Group, LLC
L1 Global Manager Pty Limited
有多少机构持有Aeon Biopharma Inc(AEON)的股份？
截至2025Q4，共有67家机构持有Aeon Biopharma Inc的股份，合计持有的股份价值约为1.90M，占公司总股份的16.13%。与2025Q3相比，机构持股有所增加，增幅为-0.27%。
哪个业务部门对Aeon Biopharma Inc的收入贡献最大？
在--，--业务部门对Aeon Biopharma Inc的收入贡献最大，创收--，占总收入的--%。
